In a report issued on November 13, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE), with a price target of $12.00. The company’s shares closed last Friday at $3.80.
According to TipRanks.com, Kulkarni is a 5-star analyst with an average return of 22.9% and a 52.6% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and ACADIA Pharmaceuticals.
Zynerba Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $13.00, representing a 244.8% upside. In a report issued on November 5, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $15.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.45 and a one-year low of $2.55. Currently, Zynerba Pharmaceuticals has an average volume of 531.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Read More on ZYNE:
